Shiji Li, Junji Ma, Wenxiu Jia, Yangyang Duan, Jingran Wang, Xiuning Zhang, Yan Han
{"title":"EIF4A3-induced circPRKAR1B promotes esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB induced CCL3 secretion.","authors":"Shiji Li, Junji Ma, Wenxiu Jia, Yangyang Duan, Jingran Wang, Xiuning Zhang, Yan Han","doi":"10.1186/s12935-025-03905-9","DOIUrl":null,"url":null,"abstract":"<p><p>Esophageal squamous cell carcinoma (ESCC) ranks as the sixth leading cause of cancer-related deaths globally, with over half of these cases occurring in China. However, the underlying molecular mechanisms of this disease are still not fully elucidated. Numerous circular RNAs (circRNAs) have been implicated in the initiation and progression of malignant tumors through diverse molecular pathways. Nevertheless, the clinical significance and functional roles of the majority of circRNAs associated with ESCC progression remain inadequately characterized. In the present study, we identified a novel circular RNA, designated as circPRKAR1B, which was found to be upregulated in esophageal squamous cell carcinoma (ESCC) tissues and associated with poor prognosis in ESCC patients. Functionally, the overexpression of circPRKAR1B enhanced the proliferation and invasive capabilities of ESCC cells. Mechanistically, circPRKAR1B facilitates the progression of ESCC by interacting with PKM2, which in turn activates the NF-κB signaling pathway, thereby promoting the secretion of CCL3. Additionally, EIF4A3 promotes the expression of circPRKAR1B by binding to its downstream flanking sequences. These findings reveal a previously unrecognized role of circular RNA in the progression of ESCC.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"262"},"PeriodicalIF":5.3000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03905-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Esophageal squamous cell carcinoma (ESCC) ranks as the sixth leading cause of cancer-related deaths globally, with over half of these cases occurring in China. However, the underlying molecular mechanisms of this disease are still not fully elucidated. Numerous circular RNAs (circRNAs) have been implicated in the initiation and progression of malignant tumors through diverse molecular pathways. Nevertheless, the clinical significance and functional roles of the majority of circRNAs associated with ESCC progression remain inadequately characterized. In the present study, we identified a novel circular RNA, designated as circPRKAR1B, which was found to be upregulated in esophageal squamous cell carcinoma (ESCC) tissues and associated with poor prognosis in ESCC patients. Functionally, the overexpression of circPRKAR1B enhanced the proliferation and invasive capabilities of ESCC cells. Mechanistically, circPRKAR1B facilitates the progression of ESCC by interacting with PKM2, which in turn activates the NF-κB signaling pathway, thereby promoting the secretion of CCL3. Additionally, EIF4A3 promotes the expression of circPRKAR1B by binding to its downstream flanking sequences. These findings reveal a previously unrecognized role of circular RNA in the progression of ESCC.
期刊介绍:
Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques.
The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors.
Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.